Key facts
- Brainomix’s last known valuation is $71.3M (Mar 2025).
- It has raised $62.2M; the latest was Later Stage VC ($23.6M) in Mar 2025.
- Notable investors include Innovate UK, Parkwalk Advisors, University of Oxford, Endeavor Greece, Modi Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Brainomix
- ·The full record, as it builds
Funding rounds
No funding rounds for Brainomix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brainomix
Developer of medical imaging biomarkers and software systems designed to support clinical decision-making for neurological and cerebrovascular diseases. The company uses artificial intelligence to provide a rapid and standardized assessment of stroke patients' CT scans, supporting consistent treatment decisions of medical professionals, irrespective of their experience or expertise, enabling healthcare professionals to make informed treatment decisions as early as possible and optimizing patient outcomes.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2010
- Employees
- 82
- Website
- brainomix.com/
- Ownership
- Privately Held (backing)
Brainomix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brainomix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brainomix in its N-PORT filings yet. We sweep new filings monthly.